D
Davide Bitetto
Researcher at University of Udine
Publications - 73
Citations - 1873
Davide Bitetto is an academic researcher from University of Udine. The author has contributed to research in topics: Liver transplantation & Hepatitis C. The author has an hindex of 21, co-authored 65 publications receiving 1726 citations.
Papers
More filters
Journal ArticleDOI
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.
Carlo Fabris,Edmondo Falleti,Annarosa Cussigh,Davide Bitetto,Elisabetta Fontanini,S. Bignulin,Sara Cmet,Ezio Fornasiere,Elisa Fumolo,Stefano Fangazio,Andrea Cerutti,Rosalba Minisini,Mario Pirisi,Pierluigi Toniutto +13 more
TL;DR: IL-28B rs12979860 C/T polymorphism T allele is more prevalent in patients with viral cirrhosis due to HCV in comparison to other aetiologies and to patients with mild chronic hepatitis C.
Journal ArticleDOI
Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.
Davide Bitetto,Carlo Fabris,Ezio Fornasiere,Corrado Pipan,Elisa Fumolo,Annarosa Cussigh,S. Bignulin,Sara Cmet,Elisabetta Fontanini,Edmondo Falleti,Romina Martinella,Mario Pirisi,Pierluigi Toniutto +12 more
TL;DR: In conclusion, vitamin D deficiency predicts an unfavourable response to antiviral treatment of RHC and vitamin D supplementation improves the probability of achieving a SVR following antiviral therapy.
Journal ArticleDOI
Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C
Davide Bitetto,Giovanna Fattovich,Carlo Fabris,E. Ceriani,Edmondo Falleti,Ezio Fornasiere,Michela Pasino,D. Ieluzzi,Annarosa Cussigh,Sara Cmet,Mario Pirisi,Pierluigi Toniutto +11 more
TL;DR: Vitamin D serum levels are complementary to the IL‐28B rs12979860 C/T polymorphism in enhancing the correct prediction of the SVR in treatment‐naïve chronic hepatitis C.
Journal ArticleDOI
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Mario Scartozzi,Luca Faloppi,Gianluca Svegliati Baroni,Cristian Loretelli,Fabio Piscaglia,Massimo Iavarone,Pierluigi Toniutto,Giammarco Fava,Samuele De Minicis,Alessandra Mandolesi,Maristella Bianconi,Riccardo Giampieri,Alessandro Granito,Floriana Facchetti,Davide Bitetto,Sara Marinelli,L. Venerandi,Sara Vavassori,S. Gemini,Antonietta D'Errico,Massimo Colombo,Luigi Bolondi,Italo Bearzi,Antonio Benedetti,Stefano Cascinu +24 more
TL;DR: Once prospectively validated, the analysis of VEGF and VEGFR SNPs may represent a clinical tool to better identify HCC patients more likely to benefit from sorafenib.
Journal ArticleDOI
PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence
Edmondo Falleti,Carlo Fabris,Sara Cmet,Annarosa Cussigh,Davide Bitetto,Elisabetta Fontanini,Ezio Fornasiere,S. Bignulin,Elisa Fumolo,Eleonora Bignulin,Mario Pirisi,Pierluigi Toniutto +11 more
TL;DR: The PNPLA3 rs738409 C>G polymorphism has been found to be strongly associated with non‐alcoholic fatty liver disease and with alcoholic liver disease, and could be a risk factor for the development of hepatocellular carcinoma in cirrhosis patients.